• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Behrouzi, Roya
    Moon, S.
    Eaton, D.
    Affiliation
    Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background Palbociclib with endocrine therapy is a first line treatment for patients with estrogen receptor positive (ER+)/ human epidermal growth factor receptor negative (HER2-) metastatic breast cancer (MBC). There is limited data regarding factors which predict progression-free survival (PFS) in patients receiving this treatment. Methods Patients with ER+/HER2- MBC starting palbociclib with letrozole at a UK cancer centre from May 2017 - Dec 2020 were retrospectively identified. Baseline patient and treatment characteristics were obtained from electronic records. PFS was calculated from date of MBC diagnosis to Mar 2021. Results 61 patients were identified with mean age 63 � 1.3 years. 2 were male. 58 (95%) were treatment naive and 3 (5%) had received a single chemotherapy line. The table shows further data. Median PFS was 27.9 months (95% CI 21.3-34.5). Patients with performance status (PS) 0 (HR 0.32, 95% CI 0.13-0.80, p=0.010), no liver metastases (HR 0.46, 95% CI 0.21-1.00, p=0.046) or bone only (non-visceral) metastases (HR 0.36, 95% CI 0.14-0.95, p=0.034) had a longer PFS than patients without these characteristics. Median PFS was 17.2 months (95% CI 6.9-27.5) in patients with liver metastases compared to 30.7 months (95% CI 23.5-37.9) in patients without. Patients with bone only metastases or PS 0 did not reach median PFS. Age, comorbidities, menopause, histology, grade, number of metastatic sites, de novo vs recurrence, dose reduction or toxicity did not predict PFS (p>0.05). In patients with recurrence, previous chemotherapy, mastectomy, relapse on endocrine treatment or relapse within 5 years were not predictive of PFS (p>0.05). Conclusions Median PFS was similar to that in the PALOMA-2 study. PS ?1, liver metastases or any visceral metastases were associated with a significantly shorter PFS. This suggests PS and metastatic pattern are important predictors of PFS and could be used to influence frequency of monitoring in patients with MBC receiving palbociclib.
    Citation
    Behrouzi R, Moon S, Eaton D. 327P Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S507.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624705
    DOI
    10.1016/j.annonc.2021.08.610
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.610
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.610
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.